Celtic ancestry, HLA phenotype and increased risk of skin cancer

British Journal of Dermatology

Volumn 138, Issue 4, 1998, Pages 627-630

  Long, C C ^a,c   Darke, C ^b   Marks, R ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Welsh Blood Service   (United Kingdom)

^c LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; HLA B ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN;

ADULT; ARTICLE; BASAL CELL CARCINOMA; CANCER RISK; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; HLA TYPING; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PHENOTYPE; PRIORITY JOURNAL; SKIN CANCER; SQUAMOUS CELL CARCINOMA;

ADULT; DISEASE SUSCEPTIBILITY; FEMALE; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HLA-DR4 ANTIGEN; HUMANS; MALE; RISK FACTORS; SKIN NEOPLASMS; SKIN PIGMENTATION; WALES;

EID: 0031921860     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1998.02173.x     Document Type: Article

References (39)

1. Long CC, Marks R. Increased risk of skin cancer: another Celticmyth? J Am Acad Dermatol 1995; 33: 658-61.
2. Roberts DL. Incidence of non-melanoma skin cancer in West Glamorgan, South Wales. Br J Dermatol 1990; 122: 399-405.
3. Bouwes Bavinck JN, Claas FHJ. The role of HLA molecules in the development of skin cancer. Hum Immunol 1994; 41: 173-9.
4. Weimar VM, Ceilley RI, Goeken JA. Cell-mediated immunity in patients with basal and squamous cell skin cancer. J Am Acad Dermatol 1980; 2: 143-7.
5. Myskowski PL, Safai B, Good RA. Decreased lymphocyte blastogenic responses in patients with multiple basal cell carcinoma. J Am Acad Dermatol 1981; 4: 711-4.
6. Czarnecki D, Mar A, Kulinskaya E. Cell-mediated immunity of patients who have had basal cell carcinomas. Acta Derm Venereol (Stockh) 1996; 76: 28-30.
7. Czarnecki D, Meehan CJ, McColl I et al. Lymphocyte counts of patients who have had skin cancer. J Am Acad Dermatol 1996; 34: 772-6.
8. Roberts DL. Is Celtic skin different? Br J Dermatol 1996; 135 (Suppl. 47): 34 (Abstr).
9. erasaki PI, Bernoco D, Park MS et al. Microdroplet testing for HLA-A, B, C, and D antigens. Am J Clin Pathol 1978; 69: 103-20.
10. Bidwell JL, Bignon JD. DNA-RFLP methods and interpretation scheme for HLA-DR and DQ typing. Eur J Immmunogenet 1991; 18: 5-22.
11. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225-35.
12. Olerup O, Aldener A, Fogdell A. HLA-DQB1 and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. Tissue Antigens 1993; 41: 119-34.
13. Bodmer JG, Marsh SGE, Albert ED et al. Nomenclature for factors of the HLA system, 1995. Tissue Antigens 1995; 46: 1-18.
14. Imanishi T, Akaza T, Kimura A et al. W15.1 allele and haplotype frequencies for HLA and complement loci in various ethnicgroups. In: HLA 1991. Proceedings of the Eleventh International Histocompatibility Workshop and Conference (Tsuji K, Aizawa M, Sasazuki T, eds). Vol. 1. New York: Oxford University Press, 1992: 1065-220.
15. Svejgaard A, Jersild C, Staub Nielsen L et al. HLA antigens and disease. Statistical and genetical considerations. Tissue Antigens 1974; 4: 95-105.
16. D'Amaro J, Bach FH. van Rood JJ et al. HLA-C associations with acute leukaemia. Lancet 1984; ii: 1176-8.
17. Streilein JW. Immunogenetic factors in skin cancer. N Engl J Med 1991; 325: 884-6.
18. Bouwes Bavinck JN, Vermeer BJ, van der Woude FJ et al. Relation between skin cancer and HLA antigens in renal transplant recipients. N Engl J Med 1991; 325: 843-8.
19. Myskowski PL, Pollack MS, Schorr E et al. Human leukocyte associations in basal cell carcinoma. J Am Acad Dermatol 1985; 12: 997-1000.
20. Czarnecki D, Lewis A. Nicholson I et al. Multiple basal cell carcinomas and HLA frequencies in southern Australia. J Am Acad Dermatol 1991; 24: 559-61.
21. Ceremile D, Contu L, Carcassi L et al. HLA and multiple skin carcinomas. Dermatologica 1988; 176: 176-81.
22. Myskowski PL. Skin cancer and HLA antigens. (Letter.) N Engl J Med 1992; 326: 765.
23. Cook DJ, Cecka JM, Terasaki PI. HLA-DR1 recipients have the highest kidney transplant survival. Transplant Proc 1987; 19: 675-7.
24. Glover MT, Bodmer J, Bodmer W et al. HLA antigen frequencies in renal transplant recipients and non-immunosuppressed patients with non-melanoma skin cancer. Eur J Cancer 1995; 29A: 520-4.
25. Bouwes Bavinck JN, Vermeer BJ, van der Woude FJ et al. Skin cancer and HLA antigens. (Letter.) N Engl J Med 1992; 326: 766.
26. Czarnecki D, Watkins F, Leahy S et al. Skin cancers and HLA frequencies in renal transplant recipients. Dermatology 1992; 185: 9-11.
27. Czarnecki D, Lewis A, Nicholson I et al. Multiple non melanoma skin cancer associated with HLA-DR7 in southern Australia. Cancer 1991; 68: 439-40.
28. Czarnecki D, Nicholson I, Tait B et al. HLA DR4 is associated with the development of multiple basal cell carcinomas and malignant melanoma. Dermatology 1993; 187: 16-18.
29. Czarnecki D, Tait B, Lewis A et al. Multiple non-melanoma skin cancer: evidence that different MHC genes are associated with different cancers. Dermatology 1994; 188: 188-90.
30. Mueller-Eckhardt G, Schendel DJ. Hundeiker M et al. Possible association between HLA-DR5 and superficial spreading melanoma (SSM). Int J Cancer 1984; 34: 751-5.
31. van Wijck R, Bouillene C. HLA antigen and susceptibility to malignant melanoma. (Letter.) Transplantation 1975; 16: 371.
32. Tarpley JL, Chretien PB, Rogentine GN et al. Histocompatibility antigens and solid malignant neoplasms. Arch Surg 1975; 110: 269-71.
33. Bergholtz B, Brennhood I, Klepp O et al. HLA antigens in malignant melanoma. In: HLA and Malignancy. New York: Liss. 1977; 175-80.
34. Pellegris G, Illeni MT, Vaglini M et al. HLA antigens in malignant melanoma patients. Tumori 1980; 66A: 51-8.
35. Barger BO, Acton RT, Soong S-J et al. Increase of HLA-DR4 in melanoma patients from Alabama. Cancer Res 1982; 42: 4276-9.
36. Czarnecki D, Nicholson I, Tait B. No HLA association with the early development of a single basal cell carcinoma. (Letter.) Dermatology 1995; 190: 88.
37. Emtestam L, Wallberg P, Aldener A et al. Multiple basal cell carcinomas: no association with HLA-DRB, HLA-DQA1 or HLA-DQB1 in Swedish patients. Br J Dermatol 1996; 134: 886-91.
38. Long CC, Marks R. Celtic ancestry and other risk factors in non-melanoma skin cancer. J Eur Acad Dermatol 1995; 5: 199-201.
39. Long CC, Marks R. The response to ultraviolet radiation and delayed hypersensitivity in Celts with skin cancer. J Eur Acad Dermatol 1996; 6: 20-6.